Figures & data
Figure 1. The sizes of the lymph nodes in the hepatic portal region were 19.1 mm and 19.5 mm (−30%~+20%; shortest diameter rule, RECIST 1.1), which were not significantly different before (A) and after (B) sorafenib monotherapy.
Figure 2. Clinical course of the patient and changes in CA125 (case 1). Sorafenib monotherapy suppressed CA125 elevation.
Figure 3. The size of the left neck lymph node was not significantly different before (A) and after (B) treatment (14.3, 10.3 mm vs. 14.3, 10.8 mm, respectively [−30%~+20%; shortest diameter rule, RECIST 1.1]).
![Figure 3. The size of the left neck lymph node was not significantly different before (A) and after (B) treatment (14.3, 10.3 mm vs. 14.3, 10.8 mm, respectively [−30%~+20%; shortest diameter rule, RECIST 1.1]).](/cms/asset/257ce3ea-6d9f-432a-a847-7a6119af5b61/kcbt_a_10926608_f0003.gif)
Figure 4. Clinical course of the patient and changes of CA125 (case 2). Sorafenib monotherapy decreased CA125 level temporarily.
